Use of selected purine analogs in neoplastic and autoimmune diseases
DOI:
https://doi.org/10.12923/Keywords:
Purine Nucleoside Analogs, Cladribine, Clofarabine, Fludarabine, PentostatinAbstract
Purine Nucleoside Analogs (PNAs) are classified as cytostatic drugs. These are used in therapy of tumours and in therapy of autoimmune diseases. In the 80s and 90s, cladribine, fludarabine and pentostatin had been accepted by the US Food and Drug Administration (FDA) for use in hematological cancer therapy [68]. The chemical structure of all PNAs is based on the nucleoside ring. The mechanism of action is multidirectional and it consists principally in the inhibition of replication and DNA repair, the inhibition of activity of DNA polymerases, as well as induction of accumulation of DNA strand breaks and apoptosis in target cells. These drugs have cytotoxic effects on both proliferating and quiescent cells. Numerous studies confirm that PNAs used in monotherapy and in combination with other cytostatic drugs or with antibodies, show good results and are relatively non-toxic.
References
1. Agura E., Cooper B., Holmes H. et al.: Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. 16, 197, 2011.
2. Al-Zahrani H., Nassar A., Al-Mohareb F. et al.: Fludarabine-Based Conditioning Chemotherapy for Allogeneic Hematopoietic Stem Cell Transplantation in Acquired Severe Aplastic Anemia. Biol of Blood and Marrow Transplant. 17, 717, 2011.
3. Andersson B.S., de Lima M., Thall P.F. et al.: Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 14, 672, 2008.
4. Andersson B.S., Valdez B.C., de Lima M. et al.: Clofarabine ± Fludarabine with Once Daily i.v. Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol of Blood and Marrow Transplant. 17, 893, 2011.
5. Bajwa R., Savelli S., Gross T.: Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. Pediatr Blood Cancer. 57, 336, 2011.
6. Bernknopf A., Rowley K., Bailey T.: A review of systemic lupus erythematosus and current treatment options. Formulary. 46, 178, 2011.
7. Bishop R., Ding X., Heller Ch. et al.: Rapid vision loss associated with fludarabine administration. Retina. 30, 1272, 2010.
8. Biswas G., Khadwal A., Arora B. et al.: Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: A single institutional experience. Indian J Cancer. 44, 137, 2007.
9. Blum K.A., Johnson J.L., Niedzwiecki D, et al.: Prolonged Follow-up After Initial Therapy With 2-Chlorodeoxyadenosine in Patients With Indolent Non-Hodgkin Lymphoma Results of Cancer and Leukemia Group B Study 9153. Cancer. 107, 2817, 2006.
10. Brown J.B., Lee G., Grimm G.R. et al.: Therapeutic benefit of pentostatin in severe IL-10-/- colitis. Inflamm Bowel Dis. 14, 880, 2008.
11. Bruno J.J., Canada T.W.: Possible pentostatin-induced symptomatic hyponatremia. Pharmacotherapy. 27, 164, 2007.
12. Bryan J., Borthakur G.: Role of rituximab in first-line treatment of chronic lymphocytic leukemia. Ther Clin Risk Manag. 22, 1, 2010.
13. Buske C., Hoster E., Dreyling M. et al.: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)R-CHOP in LPL. Leukemia. 23, 153, 2009.
14. Candoni A., Martinelli G., Toffoletti E. et al.: Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Research. 32, 1800, 2008.
15. Cannibalas F.: Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin’s Lymphoma. Seminars in Hematology. 44, S2, 2007.
16. Cervantes F., Mesa R., Barosi G.: New and Old Treatment Modalities in Primary Myelofibrosis. The Cancer Journal. 13, 377, 2007.
17. Chybicka A.: Od objawu do nowotworu. Wczesne rozpoznawanie chorób nowotworowych u dzieci. Elsevier Urban & Partner, 2009.
18. DeAngelis T., Lublin F.: Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol. 21, 261, 2008.
19. Dearden C.E., Else M., Catovsky D.: Long-term results for pentostatin and cladribine treatment of hairy cell Leukemia. Leuk Lymph. 52, 21, 2011.
20. Dillman R.O., Schreeder M.T., Hon J.K. et al.: Community-Based Phase II Trail of Pentostatin, Cyclophosphamide, and Rituximab (PCR) Biochemotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Cancer Bioth & Radiopharm. 22, 185, 2007.
21. Downs L.H.: Novel Treatment Strategies for Indolent Lymphomas: Oncology Nurse-Centric Discussions, From ONS 33rd Annual Congress in Philadelphia. PA, 2008.
22. Faderl S., Garcia-Manero G., Jabbour E. et al.: A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 12, 2011.
23. Faderl S, Garcia-Manero G, Ravandi F. et al.: Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 2008; 112: 222.
24. Farag S.S., Wood L.L., Schwartz J.E. et al.: Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia. 25, 599, 2011.
25. Fullmer A., O’Brien S., Kantarjian H. et al.: Novel therapies for relapsed acute lymphoblastic leukemia. Current Hemat Malign Reports. 4, 148, 2009.
26. Gandhi V., Plunkett W.: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 18, 584, 2006.
27. Gasperini C., Ruggieri S., Pozzilli C.: Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets. Therapeutics and Clinical Risk Management. 6, 391, 2010.
28. Gerrie A., Toze C., Ramadan K. et al.: Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials. Leuk Lymphoma. 1, 2011.
29. Giovannoni G., Comi G., Cook S. et al.: A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. N Engl J Med. 362, 416, 2010.
30. Golomb H.M.: Fifty years of hairy cell leukemia treatments. Leuk. Lymph. 52, 3, 2011.
31. Grosskreutz C., Scigliano E., Osman K. et al.: Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin. Transplant. 15, 598, 2007.
32. Guest J.F., Smith H., Sladkevicius E., et al.: Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clin Ther. 31, 2398, 2009.
33. Gutkowski K., Pluta A., Gutkowska D. et al.: Choroby o podłożu autoimmunizacyjnym. Przew. Lek. 6, 82, 2008.
34. Hagemeister F.: Rituximab for the Treatment of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukaemia. Drugs. 70, 261, 2010.
35. Hallek M., Fischer K., Fingerle-Rowson G. et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2, 1164, 2010.
36. Hartung H.P., Aktas O., Kieseier B. et al.: Development of oral cladribine for the treatment of multiple sclerosis. J Neurol. 257, 163, 2010.
37. Hartung H.P.: New oral therapies may offer improved treatment options for patients with multiple sclerosis. Curr Opin Neurol. 22, S10, 2009.
38. He G-S., Zhang X., Wu D-P. et al..: Retreatment with fludarabine and cyclosporine for one case of refractory pure red cell aplasia. Chin Med Sci J. 23, 60, 2008.
39. Henrich S., Christopherson R.I.: Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine. Leuk Mar. 22, 657, 2008.
40. Holowiecki J., Kyrcz-Krzemien S., Kuliczkowski K. et al.: Addition of cladribine to the standard daunorubicine – cytarabine (DA 3+7) remission induction protocol (DAC) contrary to adjunct of fludarabine (DAF) improves the overall survival in untreated adults with acute myeloid leukemia aged up to 60 Y: a multicenter, randomized, phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 patients. Blood (ASH Annual Meeting Abstracts). 112, 2008.
41. http://emedicine.medscape.com/article/203085-overview Abbasi M.R., Sparano J.A., Talavera F., et al..: Mantle Cell Lymphoma.
42. Inwards D.J., Fishkin P.A.S., Hillman D.V. et al.: Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone or 2-CDA and Rituximab in the North Central Cancer Treatment Group. Cancer. 113, 108, 2008.
43. Ioakimidis L., Patterson C.J., Hunter Z.R. et al..: Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 9, 62, 2009.
44. Jacobsohn D.A., Gilman A.L., Rademaker A. et al.: Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood. 12, 4354, 2009.
45. Jeha S., Razzouk B., Rytting M. et al.: Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia. J Clin Oncol. 27, 4392, 2009.
46. Johnston J.B.: Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma. 52, 43, 2011.
47. Kabir S., Garg V.K.: Therapeutic trials for systemic sclerosis: An update. Indian Journal of Dermatology, Venereology and Leprology. 74, 436, 2008.
48. Kalinka-Warzocha E., Wajs J., Lech-Maranda E. et al.: Randomized Comparison of Cladribine Alone or in Combination With Cyclophosphamide, and Cyclophosphamide, Vincristine and Prednisone in Previously Untreated Low-Grade B-Cell Non-Hodgkin Lymphoma Patients Final Report of the Polish Lymphoma Research Group. Cancer. 113, 367, 2008.
49. Kang H.J., Shin H.Y., Park J.E. et al.: Successful Engraftment with Fludarabine, Cyclophosphamide, and Thymoglobulin Conditioning Regimen in Unrelated Transplantation for Severe Aplastic Anemia: A Phase II Prospective Multicenter Study. Biol of Blood and Marrow Transplant. 16, 1582, 2010.
50. Kantarjian H.M., Jeha S., Gandhi V. et al.: Clofarabine: Past, present, and future. Leuk Lymph. 48, 1922, 2007.
51. Klein S.A., Bug G., Mousset S. et al.: Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. British J of Haemat. 154, 141, 2011.
52. Kornguth D.G., Mahajan A,, Woo S. et al.: Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation. Radiation Oncology Biol. Phys. 68, 1140, 2007.
53. Korycka A.: Perspektywy leczniczego zastosowania nowych analogów nukleozydów purynowych. Acta Haematologica Polonica. 39, 727, 2008.
54. Korycka-Wołowiec A., Zaborowska A.: Bendamustine – chemical structure, mechanism of action and possibilities of therapeutical applications. Act Haemat Pol. 40, 571, 2009.
55. Laurencet F., Ballabeni P., Rufener B. et al.: The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol. 117, 40, 2007.
56. Leist T.P., Weissert R.: Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis. Clin Neuropharm. 34, 28, 2011.
57. Maloney D.G.: What Is the Role of Maintenance Rituximab in Follicular NHL? Oncology. 22, 20, 2008.
58. Mariotti J., Taylor J., Massey P.R. et al.: The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Trans. 17, 620, 2011.
59. Minkov M., Grois N., McClain K. et al.: Langerhans Cell Histiocytosis. Histiocyte Society Evaluation and Treatment Guidelines. 2009.
60. Mossoba M.E., Onda M., Taylor J. et al.: Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res. 1, 3697, 2011.
61. Mottl H., Starý J., Cháňová M. et al.: Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymph. 47, 1881, 2006.
62. Nabhan C., Davis N., Bitran J.D. et al.: Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 117, 1490, 2011.
63. Nemecek E.R., Guthrie K.A., Sorror M.L. et al.: Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 17, 341, 2011.
64. Parmar S., Andersson B.S., Couriel D. et al.: Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 20, 294, 2011.
65. Peinert S., Tam C.S., Prince H.M. et al..: Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk & Lymph. 51, 2188, 2010.
66. Ravandi F.: Chemo-immunotherapy for hairy cell leukemia. Leuk Lymph. 52, 72, 2011.
67. Robak T., Korycka A., Lech-Maranda E. et al.: Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases. Molecules. 14, 1183, 2009.
68. Robak T., Lech-Maranda E., Korycka A. et al.: Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity. Current Medicinal Chemistry. 13, 3165, 2006.
69. Robak T.: Management of hairy cell leukemia variant. Leuk. Lymph. 52, 53, 2011.
70. Rourke M., Anderson K.C., Ghobrial I.M.: Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leukemia & Lymphoma. 51, 1779, 2010.
71. Ruan J., Coleman M., Leonard J.P.: Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challenge. Oncology (Williston Park). 23, 683, 2009.
72. Sauter C., Lamanna N., Weiss M.A.: Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 4, 1217, 2008.
73. Schmitt T., Luft T., Hegenbart U. et al.: Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Trans. 46, 580, 2011.
74. Shen S., Forero A., Meredith R.F. et al.: Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma. The Journal of Nuclear Medicine. 51, 150, 2010.
75. Shiratsuchi M., Motomura S., Abe Y. et al.: Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis. Clin Rheumatol. 27, 1207, 2008.
76. Slavin A., Kelly-Modis L., Labadia M. et al.: Pathogenic mechanisms and experimental models of multiple sclerosis. Autoimmunity. 43, 504, 2010.
77. Spurgeon S., Yu M., Phillips J.D. et al..: Cladribine: not just another purine analogue? Expert Opin Investig Drugs. 18, 1169, 2009.
78. Stepensky P., Shapira M.Y., Balashov D. et al.: Bone Marrow Transplantation for Fanconi Anemia Using Fludarabine-Based Conditioning. Biol of Blood and Marrow Transplant. 17, 1282, 2011.
79. Tadmor T.: Purine analog toxicity in patients with hairy cell leukemia. Leuk Lymphoma. 52, 38, 2011.
80. Tavil B., Aytac S., Balci Y.I. et al.:Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience. Ped Hem and Onc. 27, 517, 2010.
81. Tiu R.V., Traina F., Sekeres M.A.: Clofarabine for myelodysplastic syndromes. Expert Opin Investig Drugs. 20, 1005, 2011.
82. Treon S.P., Ioakimidis L., Soumerai J.D. et al.: Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J of Clin Onc. 27, 3830, 2009.
83. Warzocha K.: Evolving strategies in primary therapy for chronic lymphocytic leukemia. Onkologia w Praktyce Klinicznej. 3, 78, 2007.
84. Weitzman S., Braier J., Donadieu J. et al.: 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 15, 1271, 2009.
85. Wierzbowska A., Robak T., Pluta A. et al.: Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 80, 115, 2008.
86. www.aotm.gov.pl, Agencja Oceny Technologii Medycznych, Rada Konsultacyjna Stanowisko nr 41/12/2009 z dnia 8 czerwca 2009 r. w sprawie finansowania klofarabiny (Evoltra®) w leczeniu ostrej białaczki limfoblastycznej u dzieci i młodzieży.
87. Yesilipek M.A., Karasu G.T., Kupesiz A. et al.: Better Posttransplant Outcome With Fludarabine Based Conditioning in Multitransfused Fanconi Anemia Patients Who Underwent Peripheral Blood Stem Cell Transplantation. J Pediatr Hematol Oncol. 31, 512, 2009.
88. Zinzani P.L., Tani M., Pulsoni A. et al.: Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol. 9, 352, 2008.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
